MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585330 | Name: Candoxatril

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Candoxatril is a neutral endopeptidase inhibitor and natriuretic used in the treatment of hypertension.

Chemical Structure

Candoxatril
Candoxatril
CAS#123122-55-4

Theoretical Analysis

MedKoo Cat#: 585330

Name: Candoxatril

CAS#: 123122-55-4

Chemical Formula: C29H41NO7

Exact Mass: 515.2883

Molecular Weight: 515.65

Elemental Analysis: C, 67.55; H, 8.01; N, 2.72; O, 21.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Candoxatril; UK-79,300; UK79,300; UK 79,300
IUPAC/Chemical Name
4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
InChi Key
ZTWZVMIYIIVABD-RZMWZJFBSA-N
InChi Code
InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1
SMILES Code
O=C(C1CCC(NC(C2(C[C@@H](COCCOC)C(OC3=CC4=C(CCC4)C=C3)=O)CCCC2)=O)CC1)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 515.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992 Jul;10(7):607-13. PubMed PMID: 1321186. 2: Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J. 1998 Dec;19(12):1808-13. PubMed PMID: 9886723. 3: Motwani JG, Lang CC, Allen MJ, Johnson HF, Struthers AD. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther. 1993 Dec;54(6):661-9. PubMed PMID: 8275621. 4: Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8. Review. PubMed PMID: 25306450. 5: Westheim AS, Bostrøm P, Christensen CC, Parikka H, Rykke EO, Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol. 1999 Nov 15;34(6):1794-801. PubMed PMID: 10577572. 6: Elsner D, Müntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992 Aug 15;70(4):494-8. PubMed PMID: 1386491. 7: Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995 Dec;26(6 Pt 2):1160-6. PubMed PMID: 7498988. 8: Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J. 1999 Dec;138(6 Pt 1):1149-57. PubMed PMID: 10577447. 9: Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, Dargie HJ. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1999 Mar;1(1):67-72. PubMed PMID: 10937982. 10: O'Connell JE, Jardine AG, Davidson G, Connell JM. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. PubMed PMID: 1315825. 11: Burk MJ, Bienewald F, Challenger S, Derrick A, Ramsden JA. Me-DuPHOS-Rh-Catalyzed Asymmetric Synthesis of the Pivotal Glutarate Intermediate for Candoxatril. J Org Chem. 1999 Apr 30;64(9):3290-3298. PubMed PMID: 11674433. 12: Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, Mollatt AR. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica. 1997 Oct;27(10):1091-102. PubMed PMID: 9364744. 13: McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997 Mar;43(3):329-32. PubMed PMID: 9088591; PubMed Central PMCID: PMC2042739. 14: Lang CC, Motwani J, Coutie WJ, Struthers AD. Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet. 1991 Jul 27;338(8761):255. Erratum in: Lancet 1991 Aug 10;338(8763):394. PubMed PMID: 1676808. 15: Yoshida K, Kanazawa M, Casley DJ, Katopothis A, Johnston CI. Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography. J Cardiovasc Pharmacol. 1998 Nov;32(5):702-8. PubMed PMID: 9821842. 16: McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999 Jan;8(1):79-84. PubMed PMID: 15992061. 17: Eizenberg Y, Grossman E, Peleg E, Shabtai Z, Sharabi Y. Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome. J Am Soc Hypertens. 2014 Apr;8(4):227-31. doi: 10.1016/j.jash.2014.01.006. Epub 2014 Jan 24. PubMed PMID: 24560177. 18: Davidson EP, Coppey LJ, Dake B, Yorek MA. Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity. J Obes. 2011;2011. pii: 686952. doi: 10.1155/2011/686952. Epub 2010 Aug 16. PubMed PMID: 20847891; PubMed Central PMCID: PMC2933895. 19: Windeløv JA, Wewer Albrechtsen NJ, Kuhre RE, Jepsen SL, Hornburg D, Pedersen J, Jensen EP, Galsgaard KD, Winther-Sørensen M, Ørgaard A, Deacon CF, Mann M, Kissow H, Hartmann B, Holst JJ. Why is it so difficult to measure glucagon-like peptide-1 in a mouse? Diabetologia. 2017 Oct;60(10):2066-2075. doi: 10.1007/s00125-017-4347-7. Epub 2017 Jul 1. PubMed PMID: 28669086. 20: Angus RM, McCallum MJ, Nally JE, Thomson NC. No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma. Eur Respir J. 1994 Jun;7(6):1084-9. PubMed PMID: 7925877.

View History

HR011303

HR011303